TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05430919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5714
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5715
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5715
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5715
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study: NCT05800860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH001
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: OTHER
Intervention: GH001
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via inhalation
Study: NCT04751383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT06365047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8% Arginine toothpaste
Description: Investigative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 ppm F toothpaste
Description: Control
Study: NCT06214806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grocery Vouchers
Description: Participants will be given vouchers to buy groceries each month for five months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery Vouchers
Description: Participants will be given vouchers to buy groceries each month for five months.
Study: NCT05732987

Intervention type: OTHER
Intervention: Analysis of samples
Description: DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;

Intervention type: OTHER
Intervention: Analysis of samples
Description: DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
Study: NCT04582500

Intervention type: DRUG
Intervention: Iohexol
Description: Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
Study: NCT06310967

Intervention type: DRUG
Group type: OTHER
Intervention: IG3018
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: IG3018
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: IG3018
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: IG3018
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: IG3018
Description: Oral administration

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo matching IG3018
Description: Oral administration

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo matching IG3018
Description: Oral administration

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo matching IG3018
Description: Oral administration
Study: NCT05732987

Intervention type: OTHER
Intervention: Analysis of samples
Description: DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;

Intervention type: OTHER
Intervention: Analysis of samples
Description: DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;

Intervention type: OTHER
Intervention: Analysis of samples
Description: RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.

Intervention type: OTHER
Intervention: Analysis of samples
Description: RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.

Intervention type: OTHER
Intervention: Analysis of samples
Description: RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.

Intervention type: OTHER
Intervention: Analysis of samples
Description: RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
Study: NCT05998291

Intervention type: OTHER
Intervention: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
Description: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention

Intervention type: OTHER
Intervention: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
Description: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
Study: NCT05129189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22 group
Description: The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
Study: NCT05732987

Intervention type: OTHER
Intervention: Analysis of samples
Description: Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.

Intervention type: OTHER
Intervention: Analysis of samples
Description: Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.

Intervention type: OTHER
Intervention: Analysis of samples
Description: Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.

Intervention type: OTHER
Intervention: Analysis of samples
Description: Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.

Intervention type: OTHER
Intervention: Analysis of samples
Description: Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).

Intervention type: OTHER
Intervention: Analysis of samples
Description: Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).

Intervention type: OTHER
Intervention: Analysis of samples
Description: Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).

Intervention type: OTHER
Intervention: Analysis of samples
Description: Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
Study: NCT06150755

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implant supported overdenture by ball
Description: overdenture supported by two implant with ball attachment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture by bar
Description: overdenture supported by two implant splinted by intraoral welding titanuim bar
Study: NCT05695196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasal microbiota transplant (NMT)
Description: nasal microbiota transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasal microbiota transplant (NMT)
Description: nasal microbiota transplant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile saline
Study: NCT06145906

Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation plus superior vena cava isolation
Description: Pulmonary vein isolation plus superior vena cava isolation
Study: NCT06285357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG + folic acid + B12
Description: EGCG + folic acid + B12
Study: NCT06145906

Intervention type: PROCEDURE
Intervention: PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
Description: PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
Study: NCT06637215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic colorectal day surgery
Description: laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopic colorectal surgery
Description: traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
Study: NCT05722938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimodulin
Description: IMP will be administered via IV infusion on 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (human albumin 1%)
Description: IMP will be administered via IV infusion on 5 consecutive days
Study: NCT06392971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep-sea fish oil
Description: Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
Study: NCT05627765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment (ST) arm
Description: Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Intervention (II) arm
Description: Participants will receive brief advice on alcohol use based on the FRAMES model, which is a well-established and effective brief intervention for drinking.
Study: NCT06267014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality sessions
Description: One session during 10-15 minutes per week for 6 weeks.
Study: NCT05983692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium based wire
Description: Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
Study: NCT05042063

Intervention type: DEVICE
Intervention: Hyfe Cough Tracker
Description: Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough.
Study: NCT05484908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPMAS+LPE
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PE
Description: Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive internal medical treatment
Description: Patients will receive comprehensive internal medical treatment.
Study: NCT05042063

Intervention type: DEVICE
Intervention: Hyfe Cough Tracker
Description: Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough.

Intervention type: DEVICE
Intervention: Hyfe Cough Tracker
Description: Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough.

Intervention type: DEVICE
Intervention: Hyfe Air
Description: Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
Study: NCT05484908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive internal medical treatment
Description: Patients will receive comprehensive internal medical treatment.
Study: NCT05198661

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.
Description: Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection
Study: NCT05398692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual vs On Site Pulmonary Rehabilitation
Description: As part of the on site or virtual visits, the subject will receive standard pulmonary rehabilitation educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques. If post exertional malaise is present, the patient will only receive the educational sessions, no aerobic training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual vs On Site Pulmonary Rehabilitation
Description: As part of the on site or virtual visits, the subject will receive standard pulmonary rehabilitation educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques. If post exertional malaise is present, the patient will only receive the educational sessions, no aerobic training.
Study: NCT06363357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder orthosis
Description: muscle-mimicking, fabric-type shoulder orthosis
Study: NCT06325020

Intervention type: OTHER
Intervention: The assessment of patients with possible angina using the ORACLE pathway
Description: Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events.
Study: NCT04755387

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor 90mg
Description: Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60/45mg
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
Study: NCT05391958

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: base on Lean Body Mass Pattern
Description: PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: base on Lean Body Mass Pattern
Description: PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: base on Actual Body Weight
Description: PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: base on Actual Body Weight
Description: PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: obese patients
Description: obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
Study: NCT05740553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReTrieve Automated Stereognosis System
Description: An automated tactile training system that may help patients recover lost tactile function after brain injury.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReTrieve Automated Stereognosis System
Description: An automated tactile training system that may help patients recover lost tactile function after brain injury.
Study: NCT04909645

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clearsight (finger cuff)
Description: Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)\*80/CO.
Study: NCT04906096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAXALISIB
Description: Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
Study: NCT06062160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
Study: NCT05252234

Intervention type: OTHER
Intervention: Observation of hemodynamic status and post operative pain
Description: No intervention